Deucravacitinib Long-Term Efficacy Through 4 years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program. J of Skin [Internet]. 2024 Jul. 23 [cited 2026 Apr. 20];8(4):s408. Available from: https://skin.dermsquared.com/skin/article/view/2872